Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Berthold

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Cancers|June 19, 2024
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II StudyMinna Cloître, Sofian Benkhaled, Sarah Boughdad, et al.
Cancers|August 5, 2025
Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. <i>Cancers</i> 2024, <i>16</i>, 2097Minna Cloître, Sofian Benkhaled, Sarah Boughdad, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
Revue Medicale Suisse|January 28, 2021
[2020 oncology update]Giovanni Dei Tos, Ilianna Galli Vareia, Alexandre Huber, et al.
Lancet (London, England)|November 23, 2024
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designAlberto Bossi, Stéphanie Foulon, Xavier Maldonado, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Revue Medicale Suisse|January 22, 2020
[Advances in Oncology 2019]Anastasia Vernadou, Nabila Ferahta, Nuria Mederos, et al.
Clinical Genitourinary Cancer|July 25, 2016
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient ProgramDimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, et al.
Revue Medicale Suisse|December 1, 2021
[Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]Caroline Codeluppi, Françoise Ninane, Laura Jolliet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2023
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17Richard Cathomas, Sacha I Rothschild, Stefanie Hayoz, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cancers|June 19, 2024
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II StudyMinna Cloître, Sofian Benkhaled, Sarah Boughdad, et al.
Cancers|August 5, 2025
Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. <i>Cancers</i> 2024, <i>16</i>, 2097Minna Cloître, Sofian Benkhaled, Sarah Boughdad, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
Revue Medicale Suisse|January 28, 2021
[2020 oncology update]Giovanni Dei Tos, Ilianna Galli Vareia, Alexandre Huber, et al.
Lancet (London, England)|November 23, 2024
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designAlberto Bossi, Stéphanie Foulon, Xavier Maldonado, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Revue Medicale Suisse|January 22, 2020
[Advances in Oncology 2019]Anastasia Vernadou, Nabila Ferahta, Nuria Mederos, et al.
Clinical Genitourinary Cancer|July 25, 2016
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient ProgramDimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, et al.
Revue Medicale Suisse|December 1, 2021
[Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]Caroline Codeluppi, Françoise Ninane, Laura Jolliet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2023
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17Richard Cathomas, Sacha I Rothschild, Stefanie Hayoz, et al.
Pageof 4